Nov 13 (Reuters) - iRhythm Technologies Inc ::IRHYTHM TECHNOLOGIES INC FILES FOR NON-TIMELY 10-Q - SEC FILING.IRHYTHM TECHNOLOGIES- IDENTIFIED ERRORS AFFECTING PRIOR PERIODS IN THE COURSE OF PREPARING THE FORM 10-Q THAT REQUIRE FURTHER ANALYSIS.IRHYTHM TECHNOLOGIES- ERRORS MAY RESULT IN THE CORRECTION OF PREVIOUSLY ISSUED ANNUAL AND QUARTERLY FINANCIAL STATEMENTS.IRHYTHM TECHNOLOGIES- ERROR EVALUATION WILL INCLUDE ASSESSMENT OF ANY ADDITIONAL CONTROL DEFICIENCIES.
Full Article
Nov 5 (Reuters) - iRhythm Technologies Inc ::IRHYTHM TECHNOLOGIES ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.74.Q3 REVENUE $56 MILLION VERSUS REFINITIV IBES ESTIMATE OF $53.8 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $-0.40 -- REFINITIV IBES DATA.SEES FY 2019 REVENUE $215 MILLION TO $217 MILLION.SEES FY 2019 REVENUE UP 46 TO 47 PERCENT.FY2019 REVENUE VIEW $215.3 MILLION -- REFINITIV IBES DATA.GROSS MARGINS FOR FULL YEAR 2019 ARE EXPECTED TO BE BETWEEN 75.5% TO 76.5%.OPERATING EXPENSES FOR FULL YEAR 2019 ARE EXPECTED TO BE BETWEEN $210 MILLION AND $214 MILLION.
Full Article
Sept 5 (Reuters) - iRhythm Technologies Inc ::IRHYTHM TECHNOLOGIES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 1.37 MILLION COMMON SHARES PRICED AT $73.00PER SHARE.
Full Article
Sept 4 (Reuters) - iRhythm Technologies Inc ::IRHYTHM TECHNOLOGIES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.IRHYTHM TECHNOLOGIES - COMMENCED PUBLIC OFFERING OF $100 MILLION OF SHARES OF ITS COMMON STOCK.
Full Article
July 31 (Reuters) - iRhythm Technologies Inc ::IRHYTHM TECHNOLOGIES ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.46.Q2 REVENUE $53.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $49.8 MILLION.SEES FY 2019 REVENUE $212 MILLION TO $216 MILLION.SEES FY 2019 REVENUE UP 44 TO 47 PERCENT.Q2 EARNINGS PER SHARE ESTIMATE $-0.45 -- REFINITIV IBES DATA.FY2019 REVENUE VIEW $210.3 MILLION -- REFINITIV IBES DATA.OPERATING EXPENSES FOR FULL YEAR 2019 TO BE BETWEEN $198 MILLION TO $204 MILLION.
Full Article
May 7 (Reuters) - iRhythm Technologies Inc ::IRHYTHM TECHNOLOGIES ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.33.Q1 REVENUE $47.2 MILLION VERSUS REFINITIV IBES ESTIMATE OF $43.8 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.48 -- REFINITIV IBES DATA.SEES FY 2019 REVENUE $206 MILLION TO $211 MILLION.SEES FY 2019 REVENUE UP 40 TO 44 PERCENT.PROJECTS REVENUE FOR FULL YEAR 2019 TO RANGE FROM $206 MILLION TO $211 MILLION.GROSS MARGINS FOR FULL YEAR 2019 ARE EXPECTED TO RANGE FROM 75% TO 76%.OPERATING EXPENSES FOR FULL YEAR 2019 TO BE BETWEEN $193 MILLION TO $199 MILLION.
Full Article
March 4 (Reuters) - iRhythm Technologies Inc ::IRHYTHM TECHNOLOGIES FILES FOR NON-TIMELY 10-K - SEC FILING.IRHYTHM - EXPECTS TO REPORT MATERIAL WEAKNESSES IN INTERNAL CONTROL OVER FINANCIAL REPORTING.IRHYTHM TECHNOLOGIES INC - EXPECTS TO REPORT THAT ITS DISCLOSURE CONTROLS AND PROCEDURES WERE NOT EFFECTIVE AS OF DECEMBER 31, 2018..
Full Article
Feb 12 (Reuters) - iRhythm Technologies Inc ::IRHYTHM TECHNOLOGIES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES FULL YEAR 2019 FINANCIAL OUTLOOK.Q4 LOSS PER SHARE $0.61.Q4 REVENUE $43.2 MILLION VERSUS REFINITIV IBES ESTIMATE OF $40.2 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $-0.44 -- REFINITIV IBES DATA.SEES FY 2019 REVENUE $201 MILLION TO $206 MILLION.SEES FY 2019 REVENUE UP 36 TO 40 PERCENT.FY2019 REVENUE VIEW $194.9 MILLION -- REFINITIV IBES DATA.COMPANY EXPECTS SALES HEADCOUNT TO REACH APPROXIMATELY 130 TO 140 BY YEAR END 2019.
Full Article
Oct 30 (Reuters) - iRhythm Technologies Inc ::IRHYTHM TECHNOLOGIES ANNOUNCES THIRD QUARTER FINANCIAL RESULTS.Q3 REVENUE $38.1 MILLION VERSUS I/B/E/S VIEW $35.9 MILLION.SEES FY 2018 REVENUE $142 MILLION TO $144 MILLION.SEES FY 2018 REVENUE UP 49 TO 52 PERCENT.QTRLY LOSS PER SHARE $0.43.GROSS MARGINS FOR FULL YEAR 2018 ARE EXPECTED TO RANGE FROM 73.5 PCT TO 74.5 PCT.Q3 EARNINGS PER SHARE VIEW $-0.45 -- THOMSON REUTERS I/B/E/S.FY2018 REVENUE VIEW $140.7 MILLION -- THOMSON REUTERS I/B/E/S.
Full Article
Earnings vs. 
Estimates